Substance / Medication

Panobinostat

Overview

Active Ingredient
panobinostat
RxNorm CUI
1603350

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.
Armani-Tourret Marie, Gao Ce, Hartana Ciputra Adijaya et al. · Cell · 2024
PMID: 38367616RCTFull text (PMC)
A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer.
Feld Ronald, Woo Margaret M, Leighl Natasha et al. · Cancer Chemother Pharmacol · 2013
PMID: 24013574RCT
A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention.
Perez Lia, Fernandez Hugo, Kharfan-Dabaja Mohamed et al. · Blood Adv · 2021
PMID: 34242388TrialFull text (PMC)
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.
Laubach Jacob P, Tuchman Sascha A, Rosenblatt Jacalyn M et al. · Blood Cancer J · 2021
PMID: 33563894TrialFull text (PMC)
Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Islam Prioty, Rizzieri David, Lin Chenyu et al. · Cancer Invest · 2021
PMID: 34643126Trial
Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.
Mithraprabhu Sridurga, Kalff Anna, Gartlan Kate H et al. · Br J Haematol · 2021
PMID: 32945549TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Panobinostat (substance)
SNOMED CT
429068009
UMLS CUI
C1998098
RxNorm CUI
1603350

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.